Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Current state of cardiovascular research in China

Nature Reviews Cardiology volume 16, pages 575–576 (2019)Cite this article

Subjects

Scientific research drives discoveries and innovations that improve the prevention and management of cardiovascular disease. Cardiovascular research in China is thriving, as evidenced by the increasing number of publications and funding support for projects. However, data collection and the quality of publications require much improvement to propel the research field forward.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Zhou, M. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet https://doi.org/10.1016/S0140-6736(19)30427-1 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Nabel, E. G. & Braunwald, E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 54–63 (2012).

    Article  CAS  Google Scholar 

  3. Ministry of Science and Technology of the People’s Republic of China. 2017 statistics on investment in research and development [Chinese]. Ministry of Science and Technology of the People’s Republic of China http://www.most.gov.cn/mostinfo/xinxifenlei/kjtjyfzbg/kjtjbg/kjtj2018/201902/P020190225562371257913.pdf (2017).

  4. Lansky, A. et al. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet 392, 1117–1126 (2018).

    Article  CAS  Google Scholar 

  5. Han, Y. et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 313, 1336–1346 (2015).

    Article  CAS  Google Scholar 

  6. Huo, Y. et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 313, 1325–1335 (2015).

    Article  CAS  Google Scholar 

  7. Chen, S. L. et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions: DKCRUSH-V randomized trial. J. Am. Coll. Cardiol. 70, 2605–2617 (2017).

    Article  Google Scholar 

  8. Hao, Y. et al. Sex differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation 139, 1776–1785 (2019).

    Article  Google Scholar 

  9. Li, J. et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 385, 441–451 (2015).

    Article  Google Scholar 

  10. Du, X. et al. Rationale and design of the Chinese Atrial Fibrillation Registry Study. BMC Cardiovasc. Disord. 16, 130 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

The authors’ work is supported by the National Key Research and Development Program of China (2016YFC0900900 and 2016YFC0900902) and the Beijing Municipal Commission of Science and Technology (D171100006817001).

Author information

Authors and Affiliations

  1. Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China

    Jing Liu

  2. Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China

    Jing Liu

  3. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China

    Changsheng Ma

Authors
  1. Jing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changsheng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Changsheng Ma.

Ethics declarations

Competing interests

C.M. has received honoraria for presentations from AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson and Pfizer. J.L. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, J., Ma, C. Current state of cardiovascular research in China. Nat Rev Cardiol 16, 575–576 (2019). https://doi.org/10.1038/s41569-019-0253-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-019-0253-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing